Type 2 Diabetic Patients with chronic kidney Disease
Conditions
Interventions
Add-on Alogliptin
Sponsors
Department of Internal Medicine, Division of Nephrology, Juntendo University Faculty of Medicine
A Clinic named '
Meguro Orthopaedics Surgery Internal Medicine'
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with chronic kidney disease 2)Type 2 Diabetic Patients 3)Patient who has not taken DPP-4 inhibitor 4)Patient who is competent to understand the aim of this study and agree on it
Exclusion criteria
Exclusion criteria: 1)Type I and secondary diabetes 2)Severe infectious disease, before or after surgery, and severa trauma 3)Severe liver dysfunction (AST: 100 IU/l or higher) 4)Under treatment with an incretin preparation, such as other DPP-4 inhibitors, at the time of study initiation 5)Pregnant, lactating, and possibly pregnant women and those planning to become pregnant 6)Under treatment with therapeutic drugs not concomitantly administrable with incretin preparations, such as DPP-4 inhibitors, with regard to national health insurance 7)Past medical history of hypersensitivity to alogliptin 8)Judged as ineligible by clinical investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c, at-any-time blood sugar level, blood pressure, albuminurina, proteinuria, eGFR at 0, 3, 6 and 12 months after starting of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight and side effects | — |
Countries
Japan
Contacts
Public ContactHitoshi Suzuki
Juntendo University Faculty of Medicine Department of Internal Medicine, Division of Nephrology
Outcome results
None listed